Forte Biosciences, Inc.
FBRX
$6.32
-$0.34-5.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -21.85% | 15.70% | -40.64% | -9.88% | -20.40% |
| Total Depreciation and Amortization | 66.67% | 233.33% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -31.35% | 22.32% | -4.44% | -8.89% | -8.37% |
| Change in Net Operating Assets | 12.49% | -329.58% | 122.96% | -108.18% | -446.17% |
| Cash from Operations | -11.60% | 10.21% | -8.42% | -28.11% | -210.02% |
| Capital Expenditure | -82.35% | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3,595,700.00% | -- | -- | -- | -- |
| Cash from Investing | -224,818.75% | -100.00% | 100.00% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 25,258.85% | -99.98% | -- | 33.33% | -- |
| Repurchase of Common Stock | 83.33% | 70.83% | 58.33% | -- | 78.18% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -312.13% | -- | -- | -- | -- |
| Cash from Financing | 69,269.33% | -100.01% | 58.33% | -233.33% | -36.36% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 164.91% | -131.60% | 61.55% | -28.53% | -207.33% |